Keyphrases
Treatment Strategy
100%
ERK Pathway
100%
Signaling Dynamics
100%
BRAF V600E
100%
Vertical Inhibition
100%
BRAF Inhibitor (BRAFi)
28%
MEK Inhibitor (MEKi)
28%
Dabrafenib
28%
Trametinib
28%
SCH772984
28%
High Complexity
14%
Standard of Care
14%
Mathematical Model
14%
System of Ordinary Differential Equations
14%
Chemical Reaction
14%
Ordinary Differential Equations
14%
Effective Treatment
14%
Intracellular Signaling
14%
Multiple Components
14%
Drug Resistance
14%
Melanoma
14%
Early Onset
14%
Concentration Change
14%
Low-dose Treatment
14%
In Vitro Data
14%
Clinical Strategies
14%
Monotherapy
14%
In Silico
14%
Targeted Therapy
14%
Inhibitor Combination
14%
Search Space
14%
Law of Mass Action
14%
Targeted Cancer Therapy
14%
Component Concentration
14%
ERK Inhibitor
14%
Medicine and Dentistry
Low Drug Dose
100%
MEK Inhibitor
100%
Dabrafenib
100%
Trametinib
100%
Signal Transduction
50%
Malignant Neoplasm
50%
In Vitro
50%
Monotherapy
50%
Targeted Therapy
50%
Drug Resistance
50%
In Silico
50%
Melanoma
50%
Biochemistry, Genetics and Molecular Biology
Dynamics
100%
Low Drug Dose
100%
MEK Inhibitor
100%
Trametinib
100%
Dabrafenib
100%
Signal Transduction
50%
Drug Resistance
50%
Mass Action
50%
Pharmacology, Toxicology and Pharmaceutical Science
Dabrafenib
100%
Trametinib
100%
Mitogen Activated Protein Kinase Kinase Inhibitor
100%
Malignant Neoplasm
50%
Monotherapy
50%
Drug Resistance
50%
Melanoma
50%